Document is current

Any future updates will be listed below

Interleukin-17A is a potential therapeutic target predicted by proteomics for systemic sclerosis patients at high risk of pulmonary arterial hypertension

Crossref DOI link: https://doi.org/10.1038/s41598-024-76987-6

Published Online: 2024-11-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark